Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Decker

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
ESMO Open|May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)M Boukovala, D P Modest, I Ricard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
The requirements of a specialist Breast CentreA R M Wilson, L Marotti, S Bianchi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2010
Quality indicators in breast cancer careM Rosselli Del Turco, A Ponti, U Bick, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyD Balmativola, C Marchiò, M Maule, et al.
Virchows Archiv : an International Journal of Pathology|January 29, 2016
Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markersG Cserni, C A Wells, H Kaya, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2003
Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelinesG Cserni, I Amendoeira, N Apostolikas, et al.
Journal of Clinical Pathology|June 29, 2004
Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening PathologyG Cserni, I Amendoeira, N Apostolikas, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
ESMO Open|May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)M Boukovala, D P Modest, I Ricard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
The requirements of a specialist Breast CentreA R M Wilson, L Marotti, S Bianchi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2010
Quality indicators in breast cancer careM Rosselli Del Turco, A Ponti, U Bick, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyD Balmativola, C Marchiò, M Maule, et al.
Virchows Archiv : an International Journal of Pathology|January 29, 2016
Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markersG Cserni, C A Wells, H Kaya, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2003
Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelinesG Cserni, I Amendoeira, N Apostolikas, et al.
Journal of Clinical Pathology|June 29, 2004
Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening PathologyG Cserni, I Amendoeira, N Apostolikas, et al.
Pageof 24